Analysis of one case of QT prolongation induced by palbociclib capsules

doi:10.19803/j.1672-8629.20210977

Abstract

Abstract: Objective To analyze one case of QT interval prolongation caused by palbociclib capsules in our hospital so as to provide reference for clinical rational drug use. Methods To report a case of QT prolongation in a breast cancer patient receiving cyclin-dependent kinase 4/6 (CDK4/6) inhibitor (palbociclib). Results and Conclusion Palbociclib may cause QT prolongation because of individual differences or combined use with other drugs or foods, so pharmaceutical care related to cardio toxicity during medication is required, and the effect of foods or other drug components on liver drug enzymes deserves attention. If possible, blood drug concentrations should be monitored to reduce adverse reactions.

Key words: CDK4/6 inhibitor, palbociclib, QT prolongation, adverse drug reaction

CLC Number:

RAN Tuoyao, LI Chao. Analysis of one case of QT prolongation induced by palbociclib capsules[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 215-218.

References

[1] Breast Cancer Expert Committee of National Cancer Quality Control Center, Cancer Drug Clinical Research Committee of China Anti-Cancer Association. Consensus recommendations for the clinical application of cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer[J]. Chinese Journal of Oncology(中华肿瘤杂志), 2021, 43(4): 405-413.
[2] HORTOBAGYI GN, STEMMER SM, BURRIS HA, et al.Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib plus letrozole in hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer[J]. Ann Oncol, 2018, 29(7): 1541-1547.
[3] TRIPATHY D, IM SA, COLLEONI M, et al.Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial[J]. Lancet Oncol, 2018, 19(7): 904-915.
[4] YAP YG, CAMM AJ.Drug induced QT prolongation and torsades de pointes[J]. Heart, 2003, 89(11): 1363-1372.
[5] National Cencer for ADK Monitoring, China. The UK warns that CDK4/6inhibitors can cause interstitial lung disease and pneumonia[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(10): 1000.
[6] SANTONI M, OCCHIPINTI G, ROMAGNOLI E, et al.Different cardiotoxicity of palbociclib and ribociclib in breast cancer: gene expression and pharmacological data analyses, biological basis, and therapeutic implications[J]. BioDrugs, 2019, 33(6): 613-620.
[7] SLAMON DJ, NEVEN P, CHIA S, et al.Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3[J]. J Clin Oncol, 2018, 36(24): 2465-2472.
[8] BALL S, SWARUPS, SULTAN A, et al.Increased risk of cardiac conduction abnormalities with ribociclib in patients with metastatic breast cancer: a combined analysis of phase III randomized controlled trials[J]. Hematol Oncol Stem Cell Ther, 2021, 14(3): 260-262.
[9] GROENLAND SL, MARTÍNEZ-CHÁVEZ A, VAN DONGEN MGJ, et al. Clinical pharmacokinetics and pharmacodynamics of the cyclin-dependent kinase 4 and 6 inhibitors palbociclib, ribociclib, and abemaciclib[J]. Clinical Pharmacokinetics, 2020, 59(12): 1501-1520.
[10] BRAAL CL, JONGBLOED EM, WILTING SM, et al.Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences[J]. Drugs, 2021, 81(3): 317-331.
[11] DURAIRAJ C, RUIZ-GARCIA A, GAUTHIER ER, et al.Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer[J]. Anticancer Drugs, 2018, 29(3): 271-280.
[12] BEACHLER DC, DE LUISE C, JAMAL-ALLIAL A, et al.Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study[J]. BMC Cancer, 2021, 21(1): 97.
[13] KNEZHRNČIČ M, IVANOVSKI M, CÖRD, et al. Chia seeds (Salvia Hispanica L.): an overview-phytochemical profile, isolation methods, and application[J]. Molecules, 2019, 25(1): 11.
[14] YANG XF, WANG NP, ZENG FD.Effects of active components of traditional Chinese medicine on drug metabolism enzymes[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2002, 27(5): 325-327.
[15] HORN JR, HANSTEN PD, CHAN LN.Proposal for a new tool to evaluate drug interaction cases[J]. Ann Pharmacother, 2007, 41(4): 674-680.
[16] REN XY, CONG MH.Food and drug interactions: a general review[J]. Electron J Metab Nutr Cancer(肿瘤代谢与营养电子杂志), 2019, 6(1): 7-12.